Ci Capital restated their hold rating on shares of Inflarx (NASDAQ:IFRX) in a report published on Monday, AnalystRatings.com reports. Ci Capital currently has a $7.00 price target on the stock.
A number of other equities analysts have also recently issued reports on the company. ValuEngine cut Inflarx from a strong-buy rating to a buy rating in a report on Friday, June 5th. Zacks Investment Research cut Inflarx from a hold rating to a sell rating in a report on Wednesday, September 2nd. BMO Capital Markets upped their target price on Inflarx from $4.00 to $7.00 and gave the stock a market perform rating in a report on Thursday, May 21st. Raymond James lowered their target price on Inflarx from $20.00 to $19.00 and set an outperform rating for the company in a report on Friday, July 31st. Finally, BTIG Research started coverage on Inflarx in a report on Tuesday, June 16th. They issued a buy rating and a $12.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $9.58.
IFRX opened at $4.65 on Monday. The stock has a fifty day simple moving average of $4.40 and a two-hundred day simple moving average of $5.31. The company has a market cap of $122.16 million, a price-to-earnings ratio of -2.36 and a beta of 0.45. Inflarx has a 12-month low of $2.17 and a 12-month high of $9.70.
Inflarx (NASDAQ:IFRX) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.02). On average, sell-side analysts predict that Inflarx will post -1.4 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Inflarx by 3.0% during the 1st quarter. Geode Capital Management LLC now owns 90,443 shares of the company’s stock worth $345,000 after acquiring an additional 2,664 shares in the last quarter. BlackRock Inc. increased its stake in Inflarx by 40.2% in the 1st quarter. BlackRock Inc. now owns 16,473 shares of the company’s stock valued at $63,000 after buying an additional 4,721 shares during the last quarter. Wedbush Securities Inc. acquired a new stake in Inflarx in the 2nd quarter valued at $46,000. Schonfeld Strategic Advisors LLC increased its stake in Inflarx by 63.3% in the 2nd quarter. Schonfeld Strategic Advisors LLC now owns 35,240 shares of the company’s stock valued at $162,000 after buying an additional 13,655 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Inflarx by 184.7% in the 2nd quarter. Bank of America Corp DE now owns 21,900 shares of the company’s stock valued at $101,000 after buying an additional 14,209 shares during the last quarter. 13.33% of the stock is currently owned by institutional investors.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Read More: What are catch-up contributions?
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.